GSK (NYSE:GSK) Rating Increased to Strong-Buy at StockNews.com

GSK (NYSE:GSK) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday.

Other analysts have also recently issued reports about the stock. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

GSK stock opened at $34.08 on Friday. The firm has a market capitalization of $70.63 billion, a P/E ratio of 22.13, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a fifty day simple moving average of $35.16 and a two-hundred day simple moving average of $38.65. GSK has a 52 week low of $32.83 and a 52 week high of $45.92.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GSK. Eastern Bank bought a new stake in GSK during the third quarter worth approximately $26,000. Sunbelt Securities Inc. boosted its stake in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Concord Wealth Partners raised its stake in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the 2nd quarter worth approximately $37,000. Finally, Fortitude Family Office LLC bought a new stake in shares of GSK during the 3rd quarter valued at $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.